In this issue:
Machine learning model to predict type 2 diabetes onset
Hypoglycaemia risk with long-acting insulin analogues vs. NPH insulin
Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk
Dapagliflozin in women vs. men with type 2 diabetes mellitus
Improved glycaemia following CSII initiation in type 1 diabetes
Standard vs. longer intestinal bypass for RYGB in type 2 diabetes
CV, renal and metabolic outcomes of dapagliflozin for primary CV prevention
Glycaemic control, diabetic complications and dementia risk in diabetics
Dulaglutide in older patients
Validation of automated AI diabetic retinopathy screening systems
Please login below to download this issue (PDF)